Use in pregnancy: There are limited data from the use of Betnovate in pregnant women.
Topical administration of corticosteroids to pregnant animals can cause
abnormalities of fetal development (see Pharmacology: Toxicology under
Actions).
The relevance of this finding to human beings has not been established;
however, administration of Betnovate during pregnancy should only be
considered if the expected benefit to the mother outweighs the risk to
the fetus. The minimum quantity should be used for the minimum duration.
Use in lactation: The safe use of topical
corticosteroids during lactation has not been established. It is not
known whether topical administration of corticosteroids could result in
sufficient systemic absorption to produce detectable amounts in breast
milk. Administration of Betnovate during lactation should only be
considered if the expected benefit to the mother outweighs the risk to
the infant. If used during lactation, Betnovate should not be applied to
the breasts to avoid accidental ingestion by the infant.